Back to search

Article

Immune responses following third COVID-19 vaccination are reduced in patients with hematologic malignancies compared to patients with solid cancer

2021-12-22

Abstract excerpt

Not all patients with cancer, in particular those with hematogic malignancies, develop functional immunity against SARS-CoV-2 variants of concern (VOC) following COVID-19 vaccines. Durability of vaccine-induced immunity after two doses and the impact of a third dose were evaluated in CAPTURE (NCT03226886), a longitudinal prospective cohort study of vaccine responses in patients with cancer. In evaluating 316 patie...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a390ae3d-11ef-5144-84ec-4ef638f1cbb2
DOI
10.21203/rs.3.rs-1191603/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Immune responses following third COVID-19 vaccination are reduced in patients with hematologic malignancies compared to patients with solid cancerDOI 10.21203/rs.3.rs-1191603/v1
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE studySemantic proximity
Real-World Data on Neutralizing Antibody and Safety of COVID-19 Vaccine against SAR-CoV2 Wild Type and Omicron Variant in Solid Cancer PatientsSemantic proximity
Efficacy and longevity of immune response to 3 <sup>rd</sup> COVID-19 vaccine and effectiveness of a 4 <sup>th</sup> dose in severely immunocompromised patients with cancerSemantic proximity
Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelinesSemantic proximity
Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE studySemantic proximity
Immunogenicity and Omicron Neutralization Following a Third COVID-19 Vaccination in Solid Cancer Patients Previously Primed with Two Doses of Chadox1 Vaccine: A Prospective Cohort StudySemantic proximity
Humoral and Cellular Immunity to SARS-CoV-2 Vaccination in Cancer Patients: Completed Prospective Observational Study Using BNT162b2 mRNA VaccineSemantic proximity
Longitudinal Vaccine-Induced Humoral Immune Response in Cancer PatientsSemantic proximity
Breakthrough SARS-CoV-2 Infections Among Patients with Cancer Following Two and Three Doses of COVID-19 mRNA VaccinesSemantic proximity
Cancer Therapy and Immunogenicity of COVID Vaccine – CANINE StudySemantic proximity
Infection by SARS-CoV-2 with alternate frequencies of mRNA vaccine boosting for patients undergoing antineoplastic treatment for cancerSemantic proximity
Immunogenicity of SARS-CoV-2 mRNA Vaccines in Patients with Cancer: Findings from an International Collaborative Cohort StudySemantic proximity
Select a neighboring publication to make it the new centre.